Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s What Happened

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up prior to trading on Wednesday . The stock had previously closed at $17.89, but opened at $18.4350. Daiichi Sankyo shares last traded at $18.2075, with a volume of 8,958 shares traded.

Wall Street Analyst Weigh In

Several research analysts recently commented on DSNKY shares. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18. The stock has a 50 day simple moving average of $16.95 and a two-hundred day simple moving average of $17.37. The stock has a market capitalization of $33.93 billion, a P/E ratio of 21.18, a P/E/G ratio of 3.24 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.